ORIGINAL ARTICLE
Usefulness of rebiopsy in the case of mesangial pathology
 
More details
Hide details
1
Department of Immunobiology, Poznan University of Medical Sciences, Poland
 
2
Chair of Pathology and Clinical Immunology, Poznan University of Medical Sciences, Poland
 
 
Submission date: 2020-06-06
 
 
Final revision date: 2021-07-29
 
 
Acceptance date: 2021-09-21
 
 
Publication date: 2022-03-08
 
 
Pol J Pathol 2021;72(4):331-337
 
KEYWORDS
TOPICS
ABSTRACT
Immunologically different types of glomerulopathies show varied symptoms and clinical courses. Unlike in lupus nephritis, repeated biopsy is rarely performed in cases of mesangial glomerulonephritis. We reviewed 200 cases wherein rebiopsy was performed in patients with diagnosed mesangial glomerular pathology over a 30-year period and analyzed the symptoms follow-up in these cases. Further, we evaluated the morphological changes between the first and final biopsies to identify cases of histological progression and histological remission and examined the correlation between such changes and clinical symptoms. The time between the first and last biopsies ranged from 7 months to 35 years. The most common for the initial biopsy was nephrotic syndrome, followed by non-nephrotic proteinuria; other symptoms occurred rarely. Histological progression occurred at various stages of observation, ranging from within a few months to after several years. Histological progression and remission were detected in 118 and 3 patients, respectively, whereas there was no difference in morphological findings between the first and last biopsies in 79 patients. Rebiopsy is useful in patients who do not respond adequately to treatment, and especially in those with increased clinical symptoms. Moreover, electron microscopic examination is necessary to discover early signs of histological progression.
REFERENCES (40)
1.
Bhasin H, Abuelo J, Nayak R, et al. Mesangial proliferative glomerulonephritis. Lab Invest 1978; 39: 21-29.
 
2.
Brown EA, Upadhyaya K, Hayslett JP, et al. The clinical course of mesangial proliferative glomerulonephritis. Medicine 1979; 58: 295-303.
 
3.
Churg J, Sobin LH. Renal Disease. Classification and Atlas of Glomerular Diseases. Igacu-Shoin Tokyo, New York 1982; 67.
 
4.
Garin EH, Donnely WH, Geary D, et al. Nephrotic syndrome and diffuse mesangial proliferative glomerulonephritis in children. Am J Dis Child 1983; 137: 109-113.
 
5.
Heptinstall RH. Mesangioproliferative glomerulonephritis. In: Pathology of the Kidney. Little, Brown and Comp. Boston, Toronto 1983; 657-661.
 
6.
D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Quart J Med 1987; 64: 709-727.
 
7.
Yoshikawa N, Iijima K, Maehara K, et al. Mesangial changes in IgA nephropathy in children. Kidney Intern 1987; 32: 585-589.
 
8.
Silva FG, Hogg RJ. IgA nephropathy. In: Tisher CC, Brenner BM. Renal pathology JB. Lippincott Comp. Philadelphia 1989; 434-493.
 
9.
Suzuki J, Yoshikawa N, Nakamura H. A quantitative analysis of the mesangium in children with IgA nephropathy: sequential study. J Pathol 1990; 161: 57-64.
 
10.
Wayatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368: 2402-2414.
 
11.
W¹growska-Danilewicz M, Danilewicz MA. Correlation between immnoexpression of CD44, alfa-SMA and CD68+ in IgA nephropathy and in mesangial proliferative IgA-negative glomerulonephritis. Pol J Pathol 2002; 53: 155-162.
 
12.
Darvill AM, Ballatdie FW. Mesangial autoantigens in IgA nephropathy: matrix synthesis and localization. J Lab Clin Med 2006; 147: 301-309.
 
13.
Nagae H, Tsuchimoto A, Tsuruya K, et al. Clinicopathological significance of monoclonal IgA deposition in patients with IgA nephropathy. Clin Exp Nephrol 2017; 21: 266-274.
 
14.
Dyga K, Jaszczura M, Adamczyk P, et al. Nephropathy in the course of IgA vasculitis – case report. Pediatr Pol 2018; 98: 492-495.
 
15.
Habura I, Fiedorowicz K, WoŸniak A, et al. IgA nephropathy associated with coeliac disease. Cent Eur J Immunol 2019; 44: 106-108.
 
16.
Kitamura M, Obata Y, Ota Y, et al. Significance of subepithelial deposits in patients diagnosed with IgA nephropathy. Plos One 2019; 14: e0211812.
 
17.
Cohen A, Border W, Fong H, et al. Glomerulonephritis with mesangial IgM deposits. Kidney Int 1982; 21: 147-159.
 
18.
Lawler W, Wiliams G, Tarpey P, et al. IgM associated primary diffuse mesangial proliferative glomerulonephritis. J Clin Pathol 1980; 33: 1029-1038.
 
19.
Hirszel P, Yamase HT, Catney WR, et al. Mesangial proliferative glomerulonephritis with IgM deposits. Clinicopathologic analysis and evidence for morphologic transitions. Nephron 1984; 38: 100-108.
 
20.
Salla H, Mustonen J, Pasternack A, et al. Clinical follow-up of 54 patients with IgM nephropathy. Am J Nephrol 1989; 9: 124-128.
 
21.
Arias LF, Prada MC, Velez-Echeverri C, et al. IgM nephropathy in children: clinicopathology analysis. Nefrologia 2013; 33: 532-538.
 
22.
Sato M, Kjima H, Nabeshima K, et al. Primary glomerulonephritis with predominant mesangial immunoglobulin G deposits – a distinct entity? Nephron 1993; 64: 122-128.
 
23.
Daleboudt GMN, Bajema IM, Goemaere NNT, et al. The clinical revelance of repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 2009; 24: 3712-3717.
 
24.
Stoenoiu MS, Aydin S, Tektonidou M, et al. Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. Nephrol Dial Transplant 2012; 27: 1924-1930.
 
25.
Tesar V. Rare transformation in repeat renal biopsies suggests a different pathogenesis of segmental and global lesions in proliferative lupus nephritis. Nephrol Dial Transplant 2013; 28: 2929-2932.
 
26.
Zhang F, Gao E, Liang S, et al. A case of Switch from C3 glomerulonephritis to proliferative glomerulonephritis with monoclonal IgG deposits Ann Clin Lab Sci 2018; 48: 528-533.
 
27.
Downie E, Diep J, Sungala N, et al. IgM nephropathy complicated by cerebral venous sinus thrombosis: a case study. BMC Nephrol 2020; 21: 390.
 
28.
Pagni F, Galimberti S, Goffredo P, et al. The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. Nephrol Dial Transplant 2013; 28: 3014-3023.
 
29.
Navares J, Ricse M, Goma M, et al. The value of repeat biopsy in lupus nephritis flares. Medicine 2017; 96: 1-8.
 
30.
Ahmad H, Tejani A. Predictive value of repeat renal biopsies in children with nephritic syndrome. Nephron 2000; 84: 342-346.
 
31.
Zhong Y, Xu F, Li X, et al. The evolution of morphological variants of focal segmental glomerulosclerosis: a repeat biopsy-based observation. Nephrol Dial Transplant 2016; 31: 87-95.
 
32.
Salwa-¯urawska W. Focal segmental glomerulosclerosis (FSG). The value of electron-microscopic examinations, significance of rebiopsy. Pediatria Polska 1993; 38: 13-16.
 
33.
Salwa-¯urawska W, Bortkiewicz E, WoŸniak A, et al. Mesangial glomerulonephritis (GNMes) in children. Diagnostic problems, usefulness of repeated biopsy. Patologia Polska 1994; 45: 291-298.
 
34.
Cheng IK, Chan KW, Chan MK. Mesangial IgA nephropathy with steroid- responsie nephrotic syndroma. Disappearance of masangial IgA deposites following steroid-induced remission. Am J Kidney Dis 1989; 14: 361-364.
 
35.
Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 2002; 39: 493-502.
 
36.
Luo MN, Yao CW, Xu BH, et al. Continuation of immunosuppresive treatment may be necessary in IgA nephropathy patients with remission of proteinuria: Evaluation by repeat renal biopsy. Exp Ther Med 2014; 7: 553-559.
 
37.
Shen XH, Liang SS, Chen HM, et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
 
38.
J Nephrol 2015; 28: 441-449.
 
39.
Jullien P, Laurent B, Berthoux F, et al. Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome. Nephrol Dial Transplant 2020; 35: 1179-1186.
 
40.
Connor TM, Aiello V, Griffith M, et al. The natural history of immunoglobulin M nephropathy in adults. Nephrol Dial Transplant 2017; 32: 823-829.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top